Grifols, S.A., a leader in plasma-derived medicines and innovative healthcare solutions, has received certification from the European Medicines Agency (EMA) for the entire value chain of Grifols Egypt for Plasma Derivatives (GEPD) in Egypt.

This recognition positions Egypt as the first country in Africa and the Middle East to operate a fully integrated plasma collection and processing system that meets the strictest international standards throughout the entire cycle, from donor medical assessment, donation, testing and plasma processing to the supply of plasma-derived medicines to patients. This milestone enables the country, once national needs are met, to move forward with exporting surplus Egyptian plasma-derived medicines to other markets, particularly Europe.

Tomás Dagá, Vice President of Grifols Egypt and member of Grifols Board’s Strategy Committee, said: “This certification confirms the quality and rigor of the work carried out by the teams involved over these five years to create Africa’s first integrated plasma platform and align it with the most demanding international quality and safety standards. EMA’s certification of Grifols Egypt ensures that the medicines obtained from this plasma may be supplied to other markets once Egypt’s national requirements are met.”

This approval follows Egypt’s announcement that it had achieved 100% self-sufficiency in plasma-derived medicinal products thanks to Grifols, making it the sixth country in the world capable of supplying itself with medicines derived from national plasma. This milestone will allow Egypt to position itself as a regional hub to supply surplus medicines to the Africa and Middle East region.